Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic or Unresectable Cutaneous Melanoma”

232 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 232 results

Testing effectiveness (Phase 2)WithdrawnNCT01851408
What this trial is testing

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Who this might be right for
MelanomaRecurrent MelanomaStage III Melanoma+1 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT03817125
What this trial is testing

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

Who this might be right for
Metastatic Melanoma
Parker Institute for Cancer Immunotherapy 14
Not applicableStudy completedNCT00253708
What this trial is testing

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Cancer
Beth Israel Deaconess Medical Center 39
Early research (Phase 1)Study completedNCT02027961
What this trial is testing

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Who this might be right for
Melanoma
MedImmune LLC 68
Testing effectiveness (Phase 2)Study completedNCT02073123
What this trial is testing

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Who this might be right for
Metastatic MelanomaStage III MelanomaStage IV Melanoma
NewLink Genetics Corporation 132
Not applicableStudy completedNCT02310451
What this trial is testing

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes

Who this might be right for
Metastatic Melanoma
Centre Hospitalier Universitaire de Nice 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT01134614
What this trial is testing

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Who this might be right for
Advanced MelanomaMetastatic MelanomaRecurrent Melanoma+6 more
National Cancer Institute (NCI) 245
Early research (Phase 1)Study completedNCT00349206
What this trial is testing

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Who this might be right for
MelanomaRecurrent MelanomaStage III Melanoma+1 more
National Cancer Institute (NCI) 69
Testing effectiveness (Phase 2)Ended earlyNCT01551693
What this trial is testing

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
Dana-Farber Cancer Institute 3
Large-scale testing (Phase 3)Looking for participantsNCT07221734
What this trial is testing

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

Who this might be right for
Advanced (Unresectable or Metastatic) Melanoma
mAbxience Research S.L. 632
Testing effectiveness (Phase 2)Study completedNCT02259231
What this trial is testing

RTA 408 Capsules in Patients With Melanoma - REVEAL

Who this might be right for
MelanomaUnresectable (Stage III) MelanomaMetastatic (Stage IV) Melanoma
Biogen 41
Early research (Phase 1)Ended earlyNCT01783431
What this trial is testing

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

Who this might be right for
Melanoma
Medical University of South Carolina 1
Large-scale testing (Phase 3)Study completedNCT01844505
What this trial is testing

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Who this might be right for
Unresectable or Metastatic Melanoma
Bristol-Myers Squibb 945
Testing effectiveness (Phase 2)Active Not RecruitingNCT04639219
What this trial is testing

T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

Who this might be right for
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
AstraZeneca 102
Early research (Phase 1)WithdrawnNCT02915666
What this trial is testing

A Clinical Trial of Patients With Melanoma

Who this might be right for
Melanoma
University of Texas Southwestern Medical Center
Testing effectiveness (Phase 2)Study completedNCT01927419
What this trial is testing

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

Who this might be right for
Unresectable MelanomaMetastatic Melanoma
Bristol-Myers Squibb 142
Testing effectiveness (Phase 2)Study completedNCT04382664
What this trial is testing

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Who this might be right for
Malignant Melanoma
Ultimovacs ASA 156
Large-scale testing (Phase 3)Study completedNCT01763164
What this trial is testing

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Who this might be right for
Metastatic or Unresectable Cutaneous Melanoma
Pfizer 402
Testing effectiveness (Phase 2)WithdrawnNCT05572463
What this trial is testing

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Who this might be right for
Unresectable Cutaneous MelanomaMetastatic Cutaneous Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Load More Results